Λίστα αντικειμένων
Presenter: Gakis George
Participants: Prof Spyridonidis, Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou
An abstact on behalf of 28th SCHMS congress, presented by Medical student George Gakis.
Chimeric antigen receptor (CAR) T-cells have revolutionized the
standards of care for patients with hematologic malignancies. CAR T-cells,however, are linked to a variety of CAR T-cell specific adverse effects, the least understood of which is immune effector cell-associated neurotoxicity (ICANS). The goal of this review is to investigate the current published literature on the recommended ways of managing ICANS.
Establishing the best practices for handling ICANS patients is still an
active field of research, with many novel approaches being under development, such as elimination switches and CRISPR/Cas9 constructed CAR T-cells. The early recognition of ICANS clinical picture, as well as establishing the Immune Cell Encephalopathy (ICE) score which directs proper therapeutic management is of uttermost importance. It is also really important to establish common protocols when it comes to ICU admission criteria and handling protocols for ICANS and to properly train everyone involved in ICANS patient care.
Participants: Prof Spyridonidis, Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou
An abstact on behalf of 28th SCHMS congress, presented by Medical student George Gakis.
Chimeric antigen receptor (CAR) T-cells have revolutionized the
standards of care for patients with hematologic malignancies. CAR T-cells,however, are linked to a variety of CAR T-cell specific adverse effects, the least understood of which is immune effector cell-associated neurotoxicity (ICANS). The goal of this review is to investigate the current published literature on the recommended ways of managing ICANS.
Establishing the best practices for handling ICANS patients is still an
active field of research, with many novel approaches being under development, such as elimination switches and CRISPR/Cas9 constructed CAR T-cells. The early recognition of ICANS clinical picture, as well as establishing the Immune Cell Encephalopathy (ICE) score which directs proper therapeutic management is of uttermost importance. It is also really important to establish common protocols when it comes to ICU admission criteria and handling protocols for ICANS and to properly train everyone involved in ICANS patient care.